Blinded Placebo Comp-Pla+


Combined with:

Blinded NO Treatment Received Nomed

Indications and Reactions:

Role Indications Reactions
Primary
Carcinoid Tumour 75.0%
Carcinoid Syndrome 25.0%
Tumour Necrosis 100.0%
Secondary
Carcinoid Tumour 25.8%
Pancreatic Neuroendocrine Tumour 16.2%
Hypertension 5.9%
Breast Cancer 5.2%
Cardiovascular Disorder 4.5%
Constipation 4.0%
Rash 4.0%
Rhinitis Allergic 3.5%
Chronic Obstructive Pulmonary Disease 3.5%
Hepatic Neoplasm Malignant 3.5%
Pain 3.4%
Diabetes Mellitus 3.0%
Type 2 Diabetes Mellitus 2.7%
Osteoporosis 2.6%
Insomnia 2.5%
Coronary Artery Disease 2.4%
Pyrexia 2.4%
Chronic Graft Versus Host Disease 1.7%
Gastric Cancer 1.7%
Osteoporosis Prophylaxis 1.7%
Vomiting 13.0%
Pyrexia 11.7%
Tooth Extraction 9.1%
Swelling 6.5%
Urine Output Decreased 6.5%
Weight Decreased 6.5%
White Blood Cell Count Increased 6.5%
Pneumonitis 5.8%
Subileus 5.2%
Ventricular Extrasystoles 3.9%
Stomatitis 3.2%
Gastritis Erosive 2.6%
Intestinal Perforation 2.6%
Pneumonia 2.6%
Renal Failure Acute 2.6%
Staphylococcal Infection 2.6%
Thrombotic Thrombocytopenic Purpura 2.6%
Urinary Tract Infection 2.6%
Muscle Twitching 1.9%
Myocardial Infarction 1.9%

Drug Data